GLP-1 compounder issues recall for copycat Zepbound

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 22 Oct, 15:50 UTC

The notice adds to growing concerns about the safety of knockoff weight loss drugs, which have remained popular despite FDA warnings and legal pressure from Eli Lilly and Novo.

science

Sources

• T2GLP-1 compounder issues recall for copycat ZepboundBioPharma Dive / Healthcare Dive / MedTech Dive22 Oct, 15:50